Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
October 01 2020 - 09:00AM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of
Directors. Dr. Garofalo is a biopharma executive with more than 25
years of experience in global clinical development and regulatory
affairs.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201001005364/en/
Dr. Elizabeth Garofalo (Photo: Business
Wire)
“Dr. Garofalo is a highly-regarded business leader and innovator
with invaluable clinical development experience,” said Stephen R.
Biggar, M.D., Ph.D., Chairman of Acadia’s Board of Directors. “We
are excited to welcome her to the Board of Directors and look
forward to leveraging her significant CNS research and development
expertise, particularly as the company advances its innovative late
stage and growing early stage pipeline.”
“I look forward to working with the talented Acadia management
team as they continue to seek breakthroughs in the field of CNS,
pioneering new research and developing innovative new therapies to
address unmet needs,” said Dr. Garofalo.
Since 2016, Dr. Garofalo has served as the Principal for EAG
Pharma Consulting LLC. Prior to that, Dr. Garofalo served in
numerous leadership roles including as the Global Head of Clinical
Development and member of the Novartis Global Development
Leadership Team, Chair of the Novartis Portfolio Stewardship Board,
Co-Head of the Novartis Neuroscience Franchise, Head of the
Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of
Worldwide Regulatory Affairs at Pfizer, and Ann Arbor Site Head of
Neuroscience at Pfizer.
Dr. Garofalo currently serves on the board for the Institute for
Advanced Clinical Trials in Children and is the Chair of the
Business Advisory Board for the Epilepsy Foundation of America. She
earned her M.D. from the Indiana University School of Medicine and
completed fellowships in pediatric neurology and epilepsy at the
University of Michigan Medical School.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life through science. For more than 25 years we have been working
at the forefront of healthcare to bring vital solutions to people
who need them most. We developed and commercialize the first and
only approved therapy for hallucinations and delusions associated
with Parkinson’s disease psychosis. Our late-stage development
efforts are focused on dementia-related psychosis, negative
symptoms of schizophrenia and Rett syndrome, and in early-stage
clinical research we are exploring novel approaches to pain
management, and cognition and neuropsychiatric symptoms in central
nervous system disorders. For more information, visit us at
www.acadia-pharm.com and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201001005364/en/
Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858)
914-7161 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2023 to Mar 2024